IMPPAT Phytochemical information: 
(2S,3R)-3-(3,4-dihydroxyphenyl)-2-[3-(4-fluorophenyl)propylamino]-3-hydroxy-1-pyrrolidin-1-ylpropan-1-one
(2S,3R)-3-(3,4-dihydroxyphenyl)-2-[3-(4-fluorophenyl)propylamino]-3-hydroxy-1-pyrrolidin-1-ylpropan-1-one
Clinical trials
Public title (as per ICTRP)Scientific title (as per ICTRP)Trial identifier
BAY 0 9867 Cipro Pediatric Use Study (QUIP)A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious DiagnosesNCT00761462
Quinolone antibiotics for the prevention of bacterial superinfection after COVID-19 infection:a randomised, controlled, open-label, platform trialQuinolone antibiotics for the prevention of bacterial superinfection after COVID-19 infection:a randomised, controlled, open-label, platform trialChiCTR2300077260
Clinical efficacy of prevention against infectious complication after transrectal prostate biopsy and molecular and microbiological analysis of rectal Escherichia coli with quinolone-resistanceClinical efficacy of prevention against infectious complication after transrectal prostate biopsy and molecular and microbiological analysis of rectal Escherichia coli with quinolone-resistance - Clinical efficacy of prevention against infectious complication after transrectal prostate biopsyJPRN-UMIN000009755